|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multiple epidemiologic studies demonstrate associations between chronic beryllium disease (CBD), beryllium sensitization (BeS), and HLA-DPB1 alleles with a glutamic acid residue at position 69 (E69).
|
22972925 |
2012 |
|
Chronic berylliosis
|
0.400 |
SusceptibilityMutation
|
disease |
ORPHANET |
Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove.
|
22972925 |
2012 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Beryllium sensitization (BeS) and chronic beryllium disease (CBD) are determined by at least one genetic factor, a glutamic acid at position 69 (E69) of the HLA-DPB1 gene, and by exposure to beryllium.
|
21471109 |
2011 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Because inbred strains of mice have not provided good models of CBD to date, three strains of HLA-DPB1 transgenic mice in an FVB/N background were developed; each contains a single allele of HLA-DPB1 that confers a different magnitude of risk for chronic beryllium disease: HLA-DPB1*0401 (OR approximately 0.2), HLA-DPB1*0201 (OR approximately 3), and HLA-DPB1*1701 (OR approximately 46).
|
19589099 |
2009 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the NAT2 and the HLA-DPB1(G)(lu69) genes provide classic examples of how genetic susceptibility markers have a clear role in identifying disease risk in bladder cancer and chronic beryllium disease, respectively.
|
18487431 |
2008 |
|
Chronic berylliosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
HLA-DPB1 with a glutamic acid at amino acid position 69 (Glu69) confers increased risk of beryllium sensitization and is not specific for chronic beryllium disease.
|
18317020 |
2008 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BTNL2 allele associations with chronic beryllium disease in HLA-DPB1*Glu69-negative individuals.
|
17927685 |
2007 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of the study was to evaluate the evidence for potential differential susceptibility that may be associated with the physical characteristics of HLA protein molecules for which different HLA-DPB1*E69 variants code; that is, do some HLA-DPB1*E69 variants convey higher risk of beryllium sensitization and chronic beryllium disease than others.
|
16054169 |
2005 |
|
Chronic berylliosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate a prominent role for HLA-DP and LFA-1 in BAL CD4(+) T cell activation and further suggest that specific Abs to these molecules could serve as a possible therapy for chronic beryllium disease.
|
15778396 |
2005 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Several case-control studies have found an association between chronic beryllium disease (CBD) and HLA-DPB1 gene variants.
|
15273960 |
2004 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The scenarios involve glutathione-S-transferase theta 1 (GSTT1) and hematopoietic cancer in hospital workers, human leukocyte antigen coding for glutamic acid in the 69th position (HLA DPB1(E69)) and chronic beryllium disease in beryllium workers, and peripheral myelin protein 22 (PMP22) deletion and carpal tunnel syndrome in railroad track workers.
|
15018031 |
2004 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The HLA-DPB1 locus also contributed to susceptibility for sarcoidosis and, in contrast to chronic beryllium disease, a non-E(69)-containing allele, HLA-DPB1*0101, conveyed most of the risk.
|
14508706 |
2003 |
|
Chronic berylliosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evaluation of HLA-DPB1 sequence motifs in current and former beryllium workers implicated a glutamic acid residue at position 69 (HLA-DPB1(Glu69)) in chronic beryllium disease.
|
12615603 |
2003 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
|
11050177 |
2000 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Chronic beryllium disease (CBD) is associated with the allelic substitution of a Glu69 in the HLA-DPB1 gene.
|
10415070 |
1999 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Glutamic acid at position 69 in HLA-DPB1 has been reported to be strongly associated with chronic beryllium disease.
|
9655715 |
1998 |
|
Chronic berylliosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A study of chronic beryllium disease (CBD), a granulomatous disorder which is pathologically similar to sarcoidosis, has identified an association between this disease and the presence of a glutamine residue at position 69 (Glu 69+) of the B1 chain of the HLA-DPB molecule.
|
8909942 |
1996 |